- Home
- BNY vs GOSS Comparison
BNY vs GOSS Comparison
Compare BNY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- GOSS
- Stock Information
- Founded
- BNY 2001
- GOSS 2015
- Country
- BNY United States
- GOSS United States
- Employees
- BNY N/A
- GOSS N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- GOSS Health Care
- Exchange
- BNY Nasdaq
- GOSS Nasdaq
- Market Cap
- BNY 246.8M
- GOSS 237.9M
- IPO Year
- BNY N/A
- GOSS 2019
- Fundamental
- Price
- BNY $10.37
- GOSS $0.92
- Analyst Decision
- BNY
- GOSS Strong Buy
- Analyst Count
- BNY 0
- GOSS 5
- Target Price
- BNY N/A
- GOSS $9.20
- AVG Volume (30 Days)
- BNY 52.7K
- GOSS 1.0M
- Earning Date
- BNY 01-01-0001
- GOSS 03-04-2025
- Dividend Yield
- BNY 3.93%
- GOSS N/A
- EPS Growth
- BNY N/A
- GOSS N/A
- EPS
- BNY N/A
- GOSS N/A
- Revenue
- BNY N/A
- GOSS $105,322,000.00
- Revenue This Year
- BNY N/A
- GOSS N/A
- Revenue Next Year
- BNY N/A
- GOSS N/A
- P/E Ratio
- BNY N/A
- GOSS N/A
- Revenue Growth
- BNY N/A
- GOSS N/A
- 52 Week Low
- BNY $8.60
- GOSS $0.50
- 52 Week High
- BNY $10.80
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- BNY 51.22
- GOSS 50.80
- Support Level
- BNY $10.18
- GOSS $0.83
- Resistance Level
- BNY $10.28
- GOSS $1.04
- Average True Range (ATR)
- BNY 0.08
- GOSS 0.10
- MACD
- BNY 0.02
- GOSS -0.01
- Stochastic Oscillator
- BNY 87.59
- GOSS 30.65
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.